Portal de Periódicos da CAPES

The risk of second primary tumors after resection of stage I nonsmall cell lung cancer

2003; Elsevier BV; Volume: 76; Issue: 4 Linguagem: Inglês

10.1016/s0003-4975(03)00821-x

1552-6259

David C. Rice, Hyung Woo Kim, Anita L. Sabichi, Scott M. Lippman, J. Jack Lee, Brendell Williams, Ara A. Vaporciyan, W. Roy Smythe, Stephen G. Swisher, Garrett L. Walsh, Joe B. Putnam, Waun Ki Hong, Jack A. Roth,

Lung Cancer Research Studies

Abstract Background The incidence of second primary lung cancers (SPLC) after resection of nonsmall cell lung cancer (NSCLC) is estimated to be 1% to 4% per patient year. The overall effect of SPLC on survival after resection of stage I NSCLC is unknown. Here we report the incidence, management, and outcome of SPLC in a large prospective cohort of patients who underwent careful follow-up. Methods National Cancer Institute Intergroup Trial NCI #I91-0001 examined the effectiveness of isotretinoin A for chemoprevention of second primary tumors, the primary endpoint in that trial. Prospective data from patients randomly assigned to the placebo arm were analyzed. Results Five hundred sixty-nine patients underwent complete resection of pathologic stage I NSCLC. The median follow-up was 5.9 years. Second primary tumors developed in 88 (15%) patients. Of these, 49 (56%) were SPLC (incidence = 1.99/100 patient-years), with a median interval from initial surgery of 4.2 years. Second primary lung cancer never developed in patients who had never smoked (n = 44, p = 0.046; never versus ever smokers). Current smokers had a higher incidence of SPLC than former smokers (hazard ratio=1.91, p = 0.03). Age, sex, stage, histology, tumor location and initial surgery had no effect on SPLC development. Despite semiannual follow-up with chest radiographs, 12 (24%) patients had metastatic disease at the time of diagnosis of SPLC. Surgical resection was performed in 31 (63%) SPLC patients. Median survival was 4.1 years in those who underwent surgery and 1.4 years in those who did not ( p = 0.003). Overall SPLC-related mortality in the original cohort was 3.7%. Conclusions Patients who undergo surgery for SPLC can achieve prolonged survival. Despite close follow-up however many patients with SPLC present with advanced disease. That indicates a need for continued lifelong postoperative surveillance.